­
­
­
­

Inventi Impact: Orthopaedics

Articles

  • Inventi:hop/29201/19
    Association Between Concomitant csDMARDs and Clinical Response to TNF Inhibitors in Overweight Patients with Axial Spondyloarthritis
    Research 2019 : July - September
    Borja Hernández-Breijo, Chamaida Plasencia-Rodríguez, Victoria Navarro-Compán, Ana Martínez Feito, Andrea Jochems, Eva L Kneepkens, Gerrit J Wolbink, Theo Rispens, Cristina Diego, Dora Pascual-Salcedo, Alejandro Balsa

    Background: The aim of our study was to investigate the influence of conventional synthetic disease-modifying\nanti-rheumatic drugs (csDMARDs) and body mass index (BMI) on circulating drug levels and clinical response to\ntumour necrosis factor inhibitor (TNFi) therapy in axial spondyloarthritis (axSpA) patients.\nMethods: Prospective observational study during 1 year with 2 cohorts (Madrid and Amsterdam) including 180\naxSpA patients treated with standard doses of infliximab or adalimumab. Patients were stratified by BMI, being\n78 (43%) normal weight (18.5-24.9 kg/m^2) and 102 (57%) overweight/obese (less than equal to 25.0 kg/m^2). After the first year\nof treatment, TNFi trough levels were measured by capture ELISA. Clinical response to TNFi was defined as.................

    How to Cite this Article
    Attribution/ CC Compliant Citation: Hernández-Breijo, Borja, et al. \"Association between concomitant csDMARDs and clinical\nresponse to TNF inhibitors in overweight patients with axial spondyloarthritis.\" Arthritis research & therapy 21.1 (2019): 66.\nhttps://doi.org/10.1186/s13075-019-1849-3\nhttp://creativecommons.org/licenses/by/4.0/\n\nSome formatting elements, header, footer, logos, dates and pagination were modified while adapting this article.
    Download Full Text